Artery Therapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
10 Duberstein Dr, San Ramon, California,...Phone Number
(925) 230-8612Website
www.arterytx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Artery Therapeutics
Artery Therapeutics, Inc. is a pre-clinical stage biotechnology company focused on developing innovative treatments for neurodegenerative and metabolic diseases, particularly targeting conditions associated with the apolipoprotein E4 (APOE4) risk factor for Alzheimer's disease. The company utilizes a proprietary peptide library to manipulate the ABCA1 transporter, aiming to improve cognitive function and counteract the effects of neurodegenerative diseases. Additionally, Artery is developing Dipep, a therapeutic for diabetes-related cardiovascular disease, which addresses significant unmet medical needs in this area. Their intended clients include patients suffering from Alzheimer's disease, Lewy Body Dementia, traumatic brain injury, and diabetes-related cardiovascular conditions.Explore more
Artery Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Artery Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Artery Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Artery Therapeutics is spiking on competitors!
Artery Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Artery Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Artery Therapeutics has new funding data
Product Launch: Get notified when Artery Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Artery Therapeutics
Check if Artery Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Artery Therapeutics
Find more new buyers
Compare Similar Companies to Artery Therapeutics
Compare insights from companies similar to Artery Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
Artery Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Artery Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Artery Therapeutics.
Artery Therapeutics financials insights
Gather financial insights about Artery Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$37K
Artery Therapeutics Tech Stack
A closer look at the technologies used by Artery Therapeutics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Artery Therapeutics
Sign Up For FreeTo access detailed company insights
Artery Therapeutics, Inc. is a pre-clinical stage biotechnology company focused on developing innovative treatments for neurodegenerative and metabolic diseases, particularly targeting conditions associated with the apolipoprotein E4 (APOE4) risk factor for Alzheimer's disease. The company utilizes a proprietary peptide library to manipulate the AB... Read More
